• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新生儿体内苯妥英钠的消除

Phenytoin elimination in newborns.

作者信息

Bourgeois B F, Dodson W E

出版信息

Neurology. 1983 Feb;33(2):173-8. doi: 10.1212/wnl.33.2.173.

DOI:10.1212/wnl.33.2.173
PMID:6681658
Abstract

We measured the apparent half-life (t50%) of phenytoin (PHT) 30 times in 16 infants (aged 2 to 36 days) who had seizures. During the first week of life, the t50%s ranged from 6 to 140 hours. After the first week, the concentration dependence of PHT elimination was demonstrated; the t50% was related to the initial concentration (Ci). The t50% also decreased with postnatal age. Controlling for a Ci of 18 mg per liter, the average t50% decreased threefold between the first (57.3 +/- 48.2 hours) and fourth weeks (19.7 +/- 1.31). In newborns, both age-related changes and the concentration dependence of PHT elimination can cause PHT levels to decrease when constant doses are given.

摘要

我们对16名患有癫痫的婴儿(年龄在2至36天之间)进行了30次苯妥英(PHT)的表观半衰期(t50%)测定。在出生后的第一周内,t50%范围为6至140小时。第一周之后,显示出PHT消除的浓度依赖性;t50%与初始浓度(Ci)相关。t50%也随着出生后的年龄增长而降低。在控制Ci为每升18毫克的情况下,平均t50%在第一周(57.3±48.2小时)和第四周(19.7±1.31小时)之间下降了三倍。在新生儿中,当给予恒定剂量时,与年龄相关的变化以及PHT消除的浓度依赖性均可导致PHT水平降低。

相似文献

1
Phenytoin elimination in newborns.新生儿体内苯妥英钠的消除
Neurology. 1983 Feb;33(2):173-8. doi: 10.1212/wnl.33.2.173.
2
Phenytoin elimination in childhood: effect of concentration-dependent kinetics.儿童期苯妥英钠的消除:浓度依赖性动力学的影响。
Neurology. 1980 Feb;30(2):196-9. doi: 10.1212/wnl.30.2.196.
3
Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution.
Neurology. 1981 Sep;31(9):1107-12. doi: 10.1212/wnl.31.9.1107.
4
Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
Ther Drug Monit. 1985;7(4):405-10. doi: 10.1097/00007691-198512000-00007.
5
Phenobarbital and diphenylhydantoin levels in neonates with seizures.
J Pediatr. 1978 Feb;92(2):315-9. doi: 10.1016/s0022-3476(78)80034-1.
6
High intravenous phenytoin dosage requirement in a newborn infant.一名新生儿对静脉注射苯妥英钠的高剂量需求。
Neurology. 1983 Jan;33(1):106-8. doi: 10.1212/wnl.33.1.106.
7
Oral phenytoin in infancy: dose requirement, absorption, and elimination.婴儿期口服苯妥英钠:剂量需求、吸收与消除
Pediatr Pharmacol (New York). 1983;3(3-4):229-36.
8
Pharmacokinetic observations of phenytoin disposition in the newborn and young infant.苯妥英在新生儿和幼儿体内处置的药代动力学观察。
Arch Dis Child. 1977 Apr;52(4):302-9. doi: 10.1136/adc.52.4.302.
9
Oral dosing requirements for phenytoin in the first three months of life.出生后前三个月苯妥英钠的口服给药剂量要求。
J Popul Ther Clin Pharmacol. 2010 Summer;17(2):e256-61. Epub 2010 Jul 6.
10
Phenytoin in infancy and childhood.婴儿期和儿童期的苯妥英钠。
Adv Neurol. 1983;34:457-64.

引用本文的文献

1
Comparing the Efficacy and Safety of Levetiracetam Versus Phenytoin for Treating the Acute Phase of Neonatal Seizures.左乙拉西坦与苯妥英钠治疗新生儿惊厥急性期的疗效与安全性比较。
Iran J Child Neurol. 2023 Winter;17(1):65-71. doi: 10.22037/ijcn.v17i1.36008. Epub 2023 Jan 1.
2
Use of a personalized phenytoin dosing approach to manage difficult to control seizures in an infant with a SCN2A mutation.采用个性化苯妥英钠给药方法治疗一名患有SCN2A突变的婴儿难以控制的癫痫发作。
Eur J Clin Pharmacol. 2019 May;75(5):737-739. doi: 10.1007/s00228-019-02629-w. Epub 2019 Jan 15.
3
Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.
新生儿缺氧缺血性脑病惊厥的药物治疗
Paediatr Drugs. 2017 Dec;19(6):553-567. doi: 10.1007/s40272-017-0250-4.
4
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.抗癫痫药物在儿科患者中的临床药代动力学。第二部分。苯妥英、卡马西平、舒噻美、拉莫三嗪、氨己烯酸、奥卡西平和非氨酯。
Clin Pharmacokinet. 1995 Nov;29(5):341-69. doi: 10.2165/00003088-199529050-00004.
5
Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).新生儿药物生物转化原理。药代动力学-药效学界面的批判性评估(第二部分)
Clin Pharmacokinet. 1988 May;14(5):261-86. doi: 10.2165/00003088-198814050-00001.
6
Clinical pharmacology of the perinatal period and early infancy.围产期和婴儿早期的临床药理学。
Clin Pharmacokinet. 1989;17 Suppl 1:13-28. doi: 10.2165/00003088-198900171-00004.
7
Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.新生儿及儿童年龄组的治疗药物监测。问题及临床药代动力学影响。
Clin Pharmacokinet. 1990 Jul;19(1):1-10. doi: 10.2165/00003088-199019010-00001.